Mind the gap: Potential for rebounds during antiangiogenic treatment breaks

Clinical Cancer Research

Volumn 18, Issue 14, 2012, Pages 3719-3721

  Ebos, John M L ^a   Pili, Roberto ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; BEVACIZUMAB; NEUTRALIZING ANTIBODY; PLACENTAL GROWTH FACTOR; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VON HIPPEL LINDAU PROTEIN;

ANTIANGIOGENIC THERAPY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; DRUG RESPONSE; ENDOTHELIUM CELL; HISTOPATHOLOGY; HUMAN; HYPOXIA; KIDNEY CARCINOMA; METASTASIS POTENTIAL; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR FLARE;

ANIMALS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; ENDOTHELIAL CELLS; HUMANS; MICE; NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863889456     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1459     Document Type: Article

References (12)

1. Griffioen AW, Mans LA, de Graaf AMA, Nowak-Sliwinska P, de Hoog C, de Jong T, et al. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res 2012;18:3961-71.
2. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-21. (Pubitemid 44511625)
3. Levashova Z, Backer M, Hamby CV, Pizzonia J, Backer JM, Blankenberg FG. Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors. J Nucl Med 2010;51:959-66.
4. Nagengast WB, Lub-de Hooge MN, Oosting SF, den Dunnen WF, Warnders FJ, Brouwers AH, et al. VEGF-PET imaging is a non-invasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res 2010;71:143-53.
5. Wolter P, Beuselinck B, Pans S, Scḧoffski P. Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. Acta Oncol 2009;48:621-4.
6. Petrelli F, Cabiddu M, Carpo M, Ghilardi M, Barni S. Progression of intramedullary metastasis during perioperative cessation of sunitinib. Nat Rev Urol 2010;7:634-7.
7. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-21.
8. Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 2010;9:1525-35.
9. di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, et al. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res 2011;71:19-28.
10. Stein WD, Wilkerson J, Kim ST, Huang X, Motzer RJ, Fojo AT, et al. Analyzing the pivotal trial that compared sunitinib and IFN-a in renal cell carcinoma, using a method that assesses tumor regression and growth. Clin Cancer Res 2012;18:2374-81.
11. Bagri A, Berry L, Gunter B, Singh M, Kasman I,Damico LA, et al. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res 2010;16:3887-900.
12. Miles D, Harbeck N, Escudier B, Hurwitz H, Saltz L, Van Cutsem E, et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2011;29:83-8.